Elicio Extends Cash Runway to Q4 2026, Reports Positive Phase 2 Trial Observations
ELTX has more than doubled off its 52-week low of $5.15 on elevated volume (2.4× avg).
Summary
Elicio Therapeutics reported its first quarter 2026 financial results, including an improved net loss per share of $0.65 compared to $0.87 year-over-year. Critically, the company announced an extension of its cash runway into Q4 2026, which is beyond the anticipated mid-year readout for the Phase 2 AMPLIFY-7P trial. This extension was partly supported by raising $13.0 million through its at-the-market (ATM) program in Q1 and Q2 to date. The company also provided a positive clinical update, noting fewer disease progressions and deaths than projected in the ongoing blinded Phase 2 trial. This news provides crucial financial stability, addressing prior 'going concern' warnings and allowing the company to reach a significant clinical milestone without immediate funding pressure. Investors will now closely watch for the mid-year 2026 primary DFS analysis for the AMPLIFY-7P trial and the subsequent End-of-Phase 2 meeting with the FDA.
At the time of this announcement, ELTX was trading at $11.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.2M. The 52-week trading range was $5.15 to $14.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.